Hydroxyurea (Hydroxycarbamide)
Hydroxyurea is used for chronic myeloid leukemia, sickle cell disease, and polycythemia vera by inhibiting ribonucleotide reductase.
Detailed technical, regulatory, and supply information is available for commercial evaluation.
Technical Overview
Hydroxyurea (Hydroxycarbamide) – CAS 127-07-1
CAS Number
127-07-1
Category
Oncology
Therapeutic Class
Antineoplastic / Ribonucleotide reductase inhibitor
Description
Hydroxyurea is used for chronic myeloid leukemia, sickle cell disease, and polycythemia vera by inhibiting ribonucleotide reductase.
Applications
- Chronic myeloid leukemia
- Sickle cell disease
- Polycythemia vera
Handling & Supply Details
Packaging
Standard export packaging in double-lined HDPE drums or fiber drums with inner poly liners; custom pack sizes available on request.
Product Inquiry
Disclaimer
Products offered are intended strictly for R&D, registration and/or export purposes only. The responsibility for ensuring that the product does not infringe any third-party patent or intellectual property rights in the destination country rests solely with the buyer.